
    
      Following a 35-day washout of current lipid-lowering medication (if any) and adherence to a
      low-fat diet, subjects will receive either atorvastatin 20 mg for 8 weeks, OR AEGR-733 2.5 mg
      + atorvastatin 20 mg for 4 weeks followed by AEGR-733 5 mg + atorvastatin 20 mg for 4
      additional weeks. During the entire study, subjects will be instructed to follow a
      low-fat/low cholesterol diet and limit alcohol consumption to -/< 1 drink per day.
    
  